Free Trial

Amedisys, Inc. (NASDAQ:AMED) Receives Average Rating of "Hold" from Brokerages

Amedisys logo with Medical background

Amedisys, Inc. (NASDAQ:AMED - Get Free Report) has been assigned an average rating of "Hold" from the five analysts that are currently covering the firm, MarketBeat reports. Four investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $100.75.

A number of research firms have recently commented on AMED. Royal Bank of Canada reiterated an "outperform" rating and issued a $100.00 price objective on shares of Amedisys in a research note on Wednesday, April 16th. Wall Street Zen lowered Amedisys from a "strong-buy" rating to a "buy" rating in a research note on Saturday, May 24th. Finally, Stephens reiterated an "equal weight" rating and issued a $101.00 price objective on shares of Amedisys in a research note on Tuesday, March 4th.

View Our Latest Stock Report on Amedisys

Institutional Investors Weigh In On Amedisys

A number of institutional investors have recently added to or reduced their stakes in AMED. Hexagon Capital Partners LLC grew its position in Amedisys by 108.1% during the first quarter. Hexagon Capital Partners LLC now owns 310 shares of the health services provider's stock worth $29,000 after buying an additional 161 shares in the last quarter. MassMutual Private Wealth & Trust FSB grew its position in Amedisys by 56.1% during the first quarter. MassMutual Private Wealth & Trust FSB now owns 334 shares of the health services provider's stock worth $31,000 after buying an additional 120 shares in the last quarter. Fifth Third Bancorp grew its position in Amedisys by 68.1% during the first quarter. Fifth Third Bancorp now owns 348 shares of the health services provider's stock worth $32,000 after buying an additional 141 shares in the last quarter. Blue Trust Inc. grew its position in Amedisys by 55.1% during the fourth quarter. Blue Trust Inc. now owns 349 shares of the health services provider's stock worth $34,000 after buying an additional 124 shares in the last quarter. Finally, UMB Bank n.a. grew its position in Amedisys by 100.0% during the first quarter. UMB Bank n.a. now owns 386 shares of the health services provider's stock worth $36,000 after buying an additional 193 shares in the last quarter. 94.36% of the stock is owned by institutional investors and hedge funds.

Amedisys Stock Performance

Amedisys stock traded up $0.33 during trading hours on Friday, reaching $93.94. 117,182 shares of the company were exchanged, compared to its average volume of 414,495. The firm has a market cap of $3.08 billion, a price-to-earnings ratio of 37.28, a PEG ratio of 1.78 and a beta of 0.96. The company has a current ratio of 1.19, a quick ratio of 1.19 and a debt-to-equity ratio of 0.05. The stock has a 50-day moving average of $93.44 and a 200 day moving average of $91.55. Amedisys has a 12 month low of $82.15 and a 12 month high of $98.95.

Amedisys (NASDAQ:AMED - Get Free Report) last announced its earnings results on Wednesday, April 23rd. The health services provider reported $1.25 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.13 by $0.12. The firm had revenue of $594.78 million during the quarter, compared to analysts' expectations of $597.43 million. Amedisys had a return on equity of 12.20% and a net margin of 3.57%. The company's revenue was up 4.1% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.03 earnings per share. As a group, research analysts anticipate that Amedisys will post 4.4 earnings per share for the current year.

Amedisys Company Profile

(Get Free Report

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.

Recommended Stories

Analyst Recommendations for Amedisys (NASDAQ:AMED)

Should You Invest $1,000 in Amedisys Right Now?

Before you consider Amedisys, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amedisys wasn't on the list.

While Amedisys currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

NVIDIA Earnings Preview: HUGE Stock Move Ahead
These 5 Small Stocks Could Deliver Huge Returns
ACT FAST! Congress Is POURING Into This Stock

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines